Profitelligence Profitelligence · Filing Ledger Open VRTX research →

Form 8-K · Current Report · Filed 2025-05-19

Vertex Pharmaceuticals Announces Additional Stock Repurchase Program

Vertex Pharmaceuticals Incorporated has authorized a new program to repurchase up to $4.0 billion of its common stock, bringing the total authorized repurchase amount to $4.775 billion.

Filer
Vertex Pharmaceuticals Inc. VRTX · NASDAQ
Filed
Accession
0000875320-25-000199
CIK
0000875320
Signal
High impactHealthcare

Details

The new 2025 Repurchase Program complements the existing 2023 Repurchase Program, which had approximately $775 million remaining as of May 16, 2025.

Items reported

Item 8.01

Other Events

Share Repurchase Program Announced Regulatory Approval

Market reaction

Close before filing

$438.65

Next session

+1.9%

Since filing

+8.8%

Latest close

$477.10

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from VRTX reporting the same item, with the next session's move:

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another VRTX filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts